MDT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Medtronic PLC (MDT) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company offers a solid dividend yield and has shown consistent revenue growth, the stock faces headwinds such as inflationary pressures, margin constraints, and cautious analyst sentiment. Additionally, the recent sale transaction by a congress member and lack of strong proprietary trading signals suggest a wait-and-see approach is more prudent.
The MACD histogram is positive at 0.237, indicating bullish momentum, but it is contracting. RSI is neutral at 48.102, and moving averages are converging, showing no clear trend. Key support is at 78.31, and resistance is at 82.176. The stock is trading near its support level, but no strong breakout signals are present.
Medtronic reported 8% revenue growth and a 3.6% dividend yield, outperforming the S&P
The company is spinning off its diabetes care division to improve operational efficiency and focus on core growth areas.
Hedge funds have significantly increased their buying activity, up 167.88% over the last quarter.
Analysts have broadly lowered price targets, citing inflationary pressures, margin constraints, and cautious growth estimates for FY
Congress trading data shows a recent sale transaction, indicating caution from influential figures.
The stock faces challenging comps in 2027 and 2028, as well as industry-specific pressures.
No detailed financial data was provided for the latest quarter. However, Medtronic's Q4 results showed organic revenue growth above consensus, but margins were soft, and FY27 guidance was conservative.
Analyst sentiment is mixed, with some firms maintaining Buy ratings but lowering price targets. Current price targets range from $80 to $101, with a median target of $90. Analysts highlight challenges such as inflation, margin constraints, and cautious growth estimates for FY27.
